(Q43607983)

25 November 2017

Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma (English)

1 reference

25 November 2017

phase II clinical trial

0 references

linifanib

1 reference

ChEBI release 2020-05-28

2

1 reference

25 November 2017

Han Chong Toh

1

1 reference

25 November 2017

Brian I Carr

3

1 reference

25 November 2017

Jennifer J Knox

4

1 reference

25 November 2017

Sharlene Gill

5

1 reference

25 November 2017

Peter Ansell

6

1 reference

25 November 2017

Evelyn M McKeegan

7

1 reference

25 November 2017

Barry Dowell

8

1 reference

25 November 2017

Michelle Pedersen

9

1 reference

25 November 2017

Qin Qin

10

1 reference

25 November 2017

Jiang Qian

11

1 reference

25 November 2017

Frank A Scappaticci

12

1 reference

25 November 2017

Justin L Ricker

13

1 reference

25 November 2017

Dawn M Carlson

14

1 reference

25 November 2017

Wei Peng Yong

15

1 reference

25 November 2017

language of work or name

English

0 references

publication date

25 July 2012

1 reference

25 November 2017

1 reference

25 November 2017

119

1 reference

25 November 2017

2

1 reference

25 November 2017

380-387

1 reference

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

25 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Opportunities for targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Serum tumor markers for detection of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Statistics review 12: survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Current clinical use of biomarkers for epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Clinical utility of cytokeratins as tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

7 January 2021

New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

7 January 2021

Serum C-reactive protein levels predict survival in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

7 January 2021

Serum CA 125 as a marker of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27758

7 January 2021

Identifiers

DOI

10.1002/CNCR.27758

1 reference

25 November 2017

1 reference